Evidence map›Paper›PMID 38393450›Full record

ReviewMolecular neurobiology2024

Effects of Bone Marrow Mesenchymal Stem Cell-Derived Exosomes in Central Nervous System Diseases.

Miao Chai, Gang Su, Wei Chen, Juan Gao, Qionghui Wu, Jinyang Song, Zhenchang Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miao Chai *Department of Neurology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China.
Gang Su *Institute of Genetics, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730030, Gansu, China.
Wei ChenDepartment of Neurology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China.
Juan GaoDepartment of Neurology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China.
Qionghui WuDepartment of Neurology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China.
Jinyang SongDepartment of Neurology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China.
Zhenchang ZhangDepartment of Neurology, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu, China. tougao13893647595@163.com.ORCID http://orcid.org/0000-0002-1246-3745

Funding

Chinese Stroke Society cerebrovascular disease management project-Qihang Fund Qihang FundCuiying Graduate Supervisor Applicant Training Program Of Lanzhou University Second Hospital 201802"Cuiying Technology Innovation" Planning Project of Lanzhou University Second Hospital CY2021-MS-B01Health Industry Planning Project of Gansu Provincial GSWSKY2021-017Lanzhou Science and Technology Development Guiding Plan Project 2019-ZD-51Medical Innovation and Development Project of Lanzhou University lzuyxcx-2022-107Medical Innovation and Development Project of Lanzhou University lzuyxcx-2022-195National Natural Science Foundation of China 31870335Natural Science Foundation of Gansu Provincial Department of Science and Technology 20JR5RA344Natural Science Foundation of Science and Technology Department of Gansu Province 22JR5RA509NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor Open Project NLDTG2020005Science and Technology Planing Project of Chengguan District of Lanzhou City 2021-9-3
6 · The paper itself

Abstract

Central nervous system (CNS) diseases are one of the diseases that threaten human health. The delivery of drugs targeting the CNS has always been a significant challenge; the blood-brain barrier (BBB) is the main obstacle that must be overcome. The rise of bone marrow mesenchymal stem cell (BMSC) therapy has brought hope for the treatment of CNS diseases. However, the problems of low homing rate, susceptibility differentiation into astrocytes, immune rejection, and formation of iatrogenic tumors of transplanted BMSCs limit their clinical application. Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) have become a hot research topic in the treatment of CNS diseases in recent years because of their excellent histocompatibility, low immunogenicity, ease of crossing the BBB, and their ability to serve as natural carriers for treatment. This article reviews the mechanisms of BMSC-Exos in CNS diseases and provides direction for further research.

Indexed as

Central Nervous System DiseasesExosomesMesenchymal Stem CellsAnimalsBlood-Brain BarrierBone Marrow CellsHumansBMSCsCNS diseasesExosomesNeuroprotection

Identifiers

PMID38393450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.